Hepion Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Hepion Pharmaceuticals disminuyan a un ritmo anual de 23.5%, mientras que sus ingresos anuales crecerán a un ritmo de 90.4% por año. Se espera que el BPA crezca en un 9.2% al año.

Información clave

-23.5%

Tasa de crecimiento de los beneficios

9.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	21.2%
Tasa de crecimiento de los ingresos	90.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	23 May 2023

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:336 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	N/A	-82	-73	N/A	2
12/31/2024	N/A	-62	-45	N/A	2
12/31/2023	N/A	-51	-10	N/A	2
3/31/2023	N/A	-52	-33	-33	N/A
12/31/2022	N/A	-45	-35	-35	N/A
9/30/2022	N/A	-45	-38	-38	N/A
6/30/2022	N/A	-46	-36	-36	N/A
3/31/2022	N/A	-34	-34	-34	N/A
12/31/2021	N/A	-33	-31	-31	N/A
9/30/2021	N/A	-28	-29	-28	N/A
6/30/2021	N/A	-25	-21	-21	N/A
3/31/2021	N/A	-22	-19	-19	N/A
12/31/2020	N/A	-20	-16	-16	N/A
9/30/2020	N/A	-18	-14	-14	N/A
6/30/2020	N/A	-13	-12	-12	N/A
3/31/2020	N/A	-15	-10	-10	N/A
12/31/2019	N/A	-12	-8	-8	N/A
9/30/2019	N/A	-12	-10	-10	N/A
6/30/2019	N/A	-20	-12	-12	N/A
3/31/2019	N/A	-17	-14	-14	N/A
12/31/2018	N/A	-18	-16	-16	N/A
9/30/2018	N/A	-17	-13	-13	N/A
6/30/2018	N/A	-14	-15	-15	N/A
3/31/2018	N/A	-8	-16	-16	N/A
12/31/2017	N/A	-13	-18	-18	N/A
9/30/2017	N/A	-16	-20	-20	N/A
6/30/2017	N/A	-15	-19	-19	N/A
3/31/2017	N/A	-22	-19	-19	N/A
12/31/2016	N/A	-18	N/A	-18	N/A
9/30/2016	N/A	-17	N/A	-18	N/A
6/30/2016	N/A	-17	N/A	-17	N/A
3/31/2016	N/A	-17	N/A	-16	N/A
12/31/2015	N/A	-21	N/A	-15	N/A
9/30/2015	N/A	-26	N/A	-11	N/A
6/30/2015	N/A	-22	N/A	-10	N/A
3/31/2015	N/A	-12	N/A	-6	N/A
12/31/2014	N/A	-14	N/A	-4	N/A
9/30/2014	N/A	-7	N/A	-2	N/A
6/30/2014	N/A	-5	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 336 siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 336 siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 336 siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que 336 no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que 336 no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 336 se prevé que sea elevada dentro de 3 años.

Hepion Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Hepion Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Stockholder's Deficit

Hepion Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

Pharma Two B Ltd. agreed to acquire Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) in a reverse merger transaction valued at an implied equity value of approximately $58.5 million.

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease

Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice

Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding

Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study

Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023

Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Topline Results from Its Recently Completed Phase 2 Altitude-Nash Clinical Trial

High number of new directors

Hepion Pharmaceuticals, Inc. Announces Positive Results of Preclinical Studies Examining Rencofilstat as A Potential Therapeutic for Multiple Myeloma

Hepion Pharmaceuticals, Inc. Presents of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Hepion Pharmaceuticals Receives 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirements

Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'Altitude-Nash' Liver Function Trial

Hepion Pharmaceuticals, Inc. Announces Publication of Phase 2A 'Ambition' Clinical Trial Results

Hepion Pharmaceuticals, Inc. Announces Initiation of Dosing in Phase 2 'ALTITUDE-NASH' Liver Function Trial

Hepion Pharmaceuticals, Inc. Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Aug 05, 2022

Hepion Pharmaceuticals, Inc. Announces Board Changes

Hepion Pharmaceuticals, Inc. Appoints Dr. Launa J. Aspeslet as Chief Operating Officer

Hepion Pharmaceuticals Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard from Nasdaq

Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Jun 24, 2022

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals Appoints Eddie C. Cheung to Lead the Company’s Strategic Medical Affairs in Asia

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer

Hepion Pharmaceuticals, Inc Announces Additional Efficacy Data from Its Phase 2A Ambition Clinical Trial

Hepion Pharmaceuticals, Inc. Announces Positive Topline Data from Phase 2A ‘Ambition’ Nash Trial and Achieve All Primary Endpoints

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2A 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $88.4 million.

Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Hepion Pharmaceuticals Terminated the At Market Issuance Sales Agreement with B. Riley FBR, Inc

New 90-day low: €2.22

Hepion Pharmaceuticals, Inc.'s Data Safety Monitoring Board Recommends Continuation of Phase 2A 'Ambition' Clinical Trial for Treatment of Advanced Nash

New 90-day low: €2.44

Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development

Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases

New 90-day high - €3.76

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento